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Patients with liver diseases may develop alterations in all components of the hemo-
static system. Thrombocytopenia, low levels of coagulation factors and inhibitors, low 
levels of fibrinolytic proteins, and increased levels of endothelial-derived proteins such 
as von Willebrand factor are all part of the coagulopathy of liver disease. Due to con-
comitant changes in pro- and antihemostatic drivers, the net effects of these complex 
hemostatic changes have long been unclear. According to current concepts, the hemo-
static system of patients with liver disease is in an unstable balance, which explains the 
occurrence of both bleeding and thrombotic complications. This review will discuss 
etiology and management of bleeding and thrombosis in liver disease and will outline 
unsolved clinical questions. In addition, we will discuss the role of intrahepatic activa-
tion of coagulation for progression of liver disease, a novel paradigm with potential 
consequences for the general management of patients with liver disease.
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1  | INTRODUCTION
The liver is a central organ in the homeostasis of the hemostatic sys-
tem. The liver synthesizes the majority of plasma proteins involved in 
hemostasis including pro- and anticoagulant factors, pro- and antifi-
brinolytic factors, and thrombopoietin. In patients with advanced liver 
diseases complex alterations in the hemostatic system arise which are 
summarized in Table 1.1 Although it is commonly assumed many of these 
changes are related to decreased hepatic synthesis, a consumptive coag-
ulopathy of systemic or intrahepatic origin may also contribute.2,3
The net effects of the complex hemostatic changes in liver diseases 
have long been unclear. In the next sections, we will provide arguments 
for a “reset” balance in the hemostatic system in most patients with cir-
rhosis and acute liver failure.4,5 Interestingly, any of the components of 
the hemostatic system may be simultaneously altered in patients with 
liver diseases. The fact that the hemostatic system can deal relatively 
well with such extensive changes teaches us about the resilience of the 
hemostatic system in general. In this review we will summarize labora-
tory and clinical features of the altered hemostatic system in patients 
with liver diseases.
Essentials
• Patients with liver diseases may acquire substantial changes in all components of hemostasis.
• Hemostasis is in unstable balance due to simultaneous changes in pro- and antihemostatic systems.
• Intrahepatic activation of hemostasis may contribute to disease progression.
• Optimal strategies for prevention and treatment of bleeding and thrombosis are currently unknown.
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2  | WHY LIVER DISEASES WERE 
PREVIOUSLY CONSIDERED AS 
BLEEDING DISORDERS
Routine tests of hemostasis such as the prothrombin time (PT), acti-
vated partial thromboplastin time (APTT), and platelet count are fre-
quently abnormal in these patients and these test results all indicate 
a hypocoagulable status. In patients with acute liver failure, abnormal 
routine hemostasis tests are present per definition since an interna-
tional normalized ratio (INR) >1.5 is part of the definition of the syn-
drome. Although the use of the INR in this context seems peculiar 
since the INR was developed and validated only for monitoring of vita-
min K antagonists, the hepatology community misuses this test exten-
sively. It is not only part of the definition of acute liver failure, but also 
part of the prognostic score that are used to prioritize patients with 
cirrhosis on the waiting list for a liver transplant. Ironically, there is im-
mense laboratory- to- laboratory variation in the INR in plasma samples 
from patients with liver disease.6,7 This way, transplant candidates in 
centers with reagents yielding lower INR results may be at increased 
risk for dying on the waiting list.
Two clinical observations appear to agree with liver diseases as 
being a bleeding disorder. First, spontaneous bleeding complications 
in patients with cirrhosis are common. However, it has now been well 
established that the most common bleeding complication, ruptured 
esophageal varices, is unrelated to a defective hemostatic system.8 
Rather, this bleeding event relates to local vascular abnormalities 
in combination with portal hypertension. Also in acute liver failure, 
bleeding was common in studies presented in the 1970s.9 At that 
time, around one- third of patients with acute liver failure died with 
bleeding as the proximate cause of death. In a recent series, however, 
spontaneous and clinically significant bleeding is rare at around 5%, 
and bleeding very rarely results in death.10 The reasons for this sub-
stantial reduction in bleeding are unclear, but it has to be noted that 
the intensive care management of patients with acute liver failure has 
been revolutionized since the 1970s. Second, bleeding during inva-
sive procedures was a substantial problem. When liver transplantation 
was introduced as a standard clinical procedure in the 1980s, bleed-
ing complicated most, if not all, procedures.11,12 Massive amounts of 
blood products (red cell concentrates, plasma, and platelet concen-
trates) were required in many liver transplant procedures. The expla-
nation for the massive blood loss during surgery was believed to be 
the preoperative coagulopathy which further aggravated during the 
(lengthy) surgical procedure.13
During the last two decades, however, there has been a tremen-
dous decline in transfusion requirements during liver transplantation. 
In fact, more and more centers report that in a proportion of patients 
liver transplant procedures can now be performed without the require-
ment for any blood products.14–16 Part of the decline in transfusion 
requirements may be related to improvements in surgical and anes-
thesiological techniques and improvements in donor organ quality and 
preservation. However, the key factor in the decrease in transfusion 
requirements has been the understanding that preoperative correc-
tion of the abnormal routine hemostasis test results is not required, 
and may even do more harm than good. Preoperative correction of 
thrombocytopenia and elevated PT and APTT test results inevitably 
requires administration of substantial amounts of volume. In the liver 
disease patient with portal hypertension, increased plasma volume, 
and disturbed cardiac function, administration of fluids results in a fur-
ther increase in portal and central venous pressure. Thus, when plate-
let concentrates and plasma are administered with the aim to improve 
the hemostatic status, the increased portal and central venous pres-
sure may in fact promote bleeding when surgical damage is inflicted.17
3  | REBALANCED HEMOSTASIS IN 
LIVER DISEASES
The PT and APTT are only sensitive for procoagulant proteins, and 
are therefore unlikely to predict the hemostatic status of patients 
with complex hemostatic alterations. In patients with liver diseases, 
both pro- and anticoagulant factors may be present in decreased 
levels, and the hemostatic status of such patients can only be 
Changes that impair hemostasis Changes that promote hemostasis
Thrombocytopenia Elevated levels of von Willebrand Factor (VWF)
Platelet function defects Decreased levels of ADAMTS- 13
Enhanced production of nitric oxide and 
prostacyclin
Elevated levels of factor VIII
Low levels of factors II, V, VII, IX, X, and XI Decreased levels of protein C, protein S, 
antithrombin, α2- macroglobulin, and heparin 
cofactor II
Vitamin K deficiency Low levels of plasminogen
Dysfibrinogenemia
Low levels of α2- antiplasmin, factor XIII, and 
TAFI
Elevated t- PA levels
Source: Modified from the European Association for the Study of the Liver from Lisman et al.1 with 
permission.
TABLE  1 Alterations in the hemostatic 
system in patients with liver disease that 
impair (left) or promote (right) hemostasis
152  |     LISMAN ANd PORTE
appreciated by using tests that take the balance between pro- and 
anticoagulant factors into account. Similarly, the status of the pri-
mary hemostatic system and the fibrinolytic system can only be as-
sessed using global tests. Using modern thrombin generation tests, 
in which thrombomodulin was added to allow for activation of the 
protein C system, it was shown that thrombin generation in patient 
plasma was comparable to that of controls, despite substantially pro-
longed PT and APTT values in the patients.18 Thus, a concomitant 
decline in pro- and anticoagulant factors results in a reset balance 
in the coagulation system, and a similar argument applies for plate-
let function and fibrinolysis.19–22 Some studies have even shown 
evidence for enhanced hemostatic capacity in patients with liver dis-
eases, which is in sharp contrast to the old dogma of liver diseases 
as a bleeding disorder.23–29 Below we will separately address labora-
tory and clinical evidence for rebalanced hemostasis in cirrhosis and 
acute liver failure.
3.1 | The hemostatic status in patients with cirrhosis
Mild to moderate thrombocytopenia is common in cirrhosis, and 
older studies have also indicated functional platelet defects.30–32 
Thrombocytopenia in cirrhosis is multifactorial as reviewed previ-
ously.1,33 An unexplored potential contributor to the thrombocytope-
nia of liver disease are circulating histones. Histones have been shown 
to induce thrombocytopenia in mice,34 and have been implicated in 
thrombocytopenia in patients admitted to intensive care.35 As levels 
of circulating histones are slightly elevated in patients with cirrhosis, 
and substantially elevated in patients with acute liver failure,36 the 
role of histones in the thrombocytopenia of liver disease should be 
further explored. Next to their thrombocytopenia, patients with cir-
rhosis may have a prolonged skin bleeding time indicative of platelet 
defects.37 However, more recent data suggest that intrinsic platelet 
function in patients with cirrhosis is normal38 or even hyperactive,28 
although net platelet function may be decreased due to thrombocy-
topenia and/or anemia.39 Technical issues complicate the interpre-
tation of many published studies on platelet function in cirrhosis.40 
Laboratory studies using flow- based models have shown that the 
thrombocytopenia of cirrhosis may be balanced by highly elevated 
levels of von Willebrand factor (VWF).20,38 In addition, plasma levels 
of a disintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13 (ADAMTS13) are decreased in patients with liver 
disease.41 Decreased ADAMTS13 does not result in an increase in the 
multimeric size of VWF. In fact, a decrease of higher molecular weight 
multimers is present in plasma from patients with cirrhosis, which is 
presumably related to proteolysis by other VWF- cleaving proteases 
such as plasmin.42,43 Nevertheless, decreased ADAMTS13 in cirrhosis 
may promote primary hemostasis, as ADAMTS13 is also responsible 
for regulation of thrombus growth by proteolysis of VWF within a 
growing thrombus.44 Clinical evidence for an important compensa-
tory role of VWF in the thrombocytopenia of cirrhosis may be de-
duced from studies in which thrombopoietin receptor agonists have 
been used to increase the platelet count in patients with cirrhosis. 
Elevation of the platelet count was associated with an increased risk 
of thrombosis, which may be attributable to the high VWF levels,45,46 
although alternative explanations for the thrombotic risk of throm-
bopoietin receptor agonists in these patients cannot be excluded. On 
the other hand, it has been suggested that thrombocytopenia (and not 
prolonged routine coagulation tests) increase the risk for procedure- 
associated bleeding,47 although not all studies agree.48
Thrombin generation tests have shown normal- to- increased hemo-
static potential in plasma from patients with cirrhosis when thrombin 
generation tests were performed in the presence of thrombomod-
ulin.18,23–27 Initially, it was concluded that the endogenous thrombin 
potential (ETP) in cirrhosis is normal18, but multiple subsequent studies 
have actually shown increased thrombin generation.23–27 Increasingly, 
the coagulation status of a patient with cirrhosis is not reported as the 
thrombin generating capacity, but rather as a ratio between thrombin 
generation tests performed in absence and presence of thrombomod-
ulin, or as ratios between FVIII and protein C.49–51 Unfavorable ratios 
are referred to as “procoagulant imbalance,” which we feel is confusing 
terminology. We have argued against the use of ETP or FVIII/protein 
C ratios as estimates of hemostatic capacity as these ratios may be 
misleading, are difficult to interpret, and have no clear clinical correla-
tion.52 Rather, we feel that ETP results obtained in the presence of 
thrombomodulin are the most adequate representation of coagulation 
status in patients with complex alterations in their hemostatic system. 
Nevertheless, these studies have demonstrated that the PT and APTT 
are inadequate to estimate the hemostatic status of patients with 
cirrhosis.
Besides preserved thrombin generating capacity, we have recently 
demonstrated procoagulant properties of the fibrinogen molecule. 
Despite reduced fibrinogen plasma levels, fibrin clot permeability, a 
measure of clot structure and quality, was decreased in patients with 
cirrhosis, which was attributable to oxidative modifications in the fi-
brinogen molecule.29
Cirrhosis has long been thought to be associated with a hyperfi-
brinolytic status related to increased levels of tissue- type plasminogen 
activator which are insufficiently balanced by fibrinolytic inhibitors.53 
However, using a global plasma- based assay we demonstrated that the 
fibrinolytic system in cirrhosis was rebalanced due to a commensurate 
decline in pro- and antifibrinolytic factors.19 Importantly, a typical fi-
brinolytic bleeding rarely occurs in non- surgical patients with cirrho-
sis, which supports the laboratory evidence of rebalanced fibrinolysis. 
Nevertheless, some studies using plasma- based or whole blood assays 
indicating accelerated fibrinolysis in cirrhosis have questioned our 
findings.54,55 Conversely, in large series of patients that were studied 
with thromboelastography, none had a fibrinolysis rate outside of the 
reference range.25,56
Whole blood clot formation as tested by viscoelastic tests have 
been demonstrated to be normal in patients with cirrhosis,56 but 
also number of studies have demonstrated profound hypocoagula-
bility.57–60 Viscoelastic tests have (whole blood) clot formation as the 
endpoint, which is an obvious advantage to thrombin generation tests 
or routine diagnostic tests such as the PT, which have thrombin gen-
eration or the time point of fibrinogen to fibrin conversion in plasma 
as the endpoint. In addition, viscoelastic tests are sensitive for the 
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activity of coagulation factor XIII.61 However, an obvious limitation of 
viscoelastic tests in patients with complex disorders of hemostasis is 
that it is not a true representation of hemostatic balance as it lacks 
activation of the anticoagulant protein C system, and is insensitive for 
von Willebrand factor. Given the profound changes in VWF and the 
protein C pathway in cirrhosis, it appears unlikely that thromboelas-
tography forms a valid representation of overall hemostatic balance 
in these patients.
It has to be noted that most studies on the hemostatic balance 
in patients with cirrhosis have been performed in mixed cohorts of 
relatively well- compensated patients. Although hemostatic changes in 
patients with cirrhosis from different etiologies are similar, they are 
certainly not identical. For example, patients with cholestatic cirrho-
sis appear in a more hypercoagulable state as compared to patients 
with noncholestatic cirrhosis,62 and patients with nonalcoholic fatty 
liver disease associated cirrhosis are somewhat more prothrombotic 
as compared to patients with alcohol- induced cirrhosis.63 Also, it 
has been hypothesized that the hemostatic balance may be no lon-
ger maintained in patients with decompensated disease. However, 
in recent studies we demonstrated normo- to hypercoagulability in 
patients with acutely decompensated cirrhosis and acute- on- chronic 
liver failure using thrombin generation tests (unpublished data).
Although the hemostatic status of patients with cirrhosis appears 
in balance, there are clear hypo- and hypercoagulable features which 
may contribute to bleeding or thrombosis. Hypocoagulable features 
include hypofibrinogenemia,29 decreased clot formation and sta-
bility in some studies using viscoelastic testing,60 delayed fibrin po-
lymerization,64 and hyperfibrinolysis.65 Hypercoagulable features 
include platelet hyperreactivity,28 enhanced thrombin generation,23–27 
 increased production of intravascular tissue factor,66 and prothrom-
botic properties of the fibrin clot.29
3.2 | The hemostatic status of patients with acute 
liver failure
Thrombocytopenia is less common in patients with acute liver failure 
as compared to cirrhosis. The pathophysiology of thrombocytopenia 
in acute liver failure has not been extensively addressed, but recent 
studies indicate that platelet activation may contribute.67 Substantially 
elevated levels of highly procoagulant microparticles, mainly from 
platelet origin, have been demonstrated in plasma from patients with 
acute liver failure. These microparticles have been suggested to be 
the results of platelet fragmentation in a process resembling dissemi-
nated intravascular coagulation of sepsis. Indeed, intravascular (or in-
trahepatic) activation of hemostasis has been demonstrated in animal 
models of acute liver failure as will be outlined in the section on intra-
hepatic thrombosis as a contributor of disease progression. Whether 
the circulating procoagulant microparticles have a role in hemostasis 
has not been directly investigated.
Patients with acute liver failure, similar to patients with cirrhosis, 
have highly elevated levels of VWF and substantially decreased lev-
els of ADAMTS13.22 Although ADAMTS13 levels are undetectable 
in a proportion of patients, a reduced proportion of high molecular 
weight multimers was detected, which is likely related to VWF pro-
teolysis by proteases other than ADAMTS13.20 Interestingly, levels 
of ADAMTS13 measured on admission to the hospital have been re-
lated to outcome, which has been proposed to be a consequence of 
increased formation of intrahepatic platelet thrombi in those patients 
with low levels of ADAMTS13.
The alterations in coagulation proteins are more extensive in 
patients with acute liver failure compared to patients with cirrho-
sis. Levels of the liver- derived factors are substantially decreased, 
and can become as low as 1–10% of normal.21,68 Nevertheless, 
thrombomodulin- modified thrombin generation in patients with acute 
liver failure was shown to be normal or increased relative to healthy 
controls.21,68 In addition, thromboelastography test results are consis-
tent with rebalanced hemostasis in acute liver failure.69
In contrast to cirrhosis, acute liver failure is characterized by a pro-
found hypofibrinolytic status, which is likely related to substantially 
elevated plasma levels of PAI- 1 and low plasminogen levels.21
3.3 | Clinical evidence of intact hemostatic capacity 
in cirrhosis and acute liver failure
What clinical evidence exists to support the theory of rebalanced 
hemostasis in liver disease and to refute the value of routine diag-
nostic tests such as the PT and platelet count in assessing hemo-
static competence in liver diseases? First, more and more centers 
report transfusion- free liver transplantation in a substantial pro-
portion of patients.14–16 Although transfusion requirements still 
vary widely between centers,70 there is no doubt that this lengthy 
procedure with substantial surgical damage does not per se result 
in major blood loss. A recent study from a single center showed 
that almost 80% of a series of 700 consecutive patients were 
transplanted without any transfusion requirements.16 These data 
strongly argue against liver disease being associated with a bleed-
ing diathesis. Secondly, although bleeding is common is cirrhosis, 
most bleeding episodes are unrelated to hemostatic dysfunction 
(eg, bleeding from ruptured esophageal varices). Bleeding problems 
such as bruising, purpura, epistaxis, gingival bleeding, menorrhagia, 
and bleeding associated with invasive procedures may be related 
to defective hemostasis. However, in some cases, elevated venous 
pressure may contribute to bleeding problems that at first sight ap-
pear as a consequence of deranged hemostasis. Interestingly, the 
extent of coagulopathy as measured by the PT or platelet count 
does not appear predictive of bleeding complications.71 In acute 
liver failure, clinically significant bleeding is rare, and in contrast 
to patients with cirrhosis bleeding from esophageal varices is vir-
tually absent, which is explained largely by the usual absence of 
portal hypertension. Third, patients with liver disease are not pro-
tected from thrombotic events, and increasing clinical data refute 
the twentieth- century concept of patients with liver diseases being 
“auto- anticoagulated.” Cirrhosis has been identified as a risk fac-
tor for venous thrombosis,72 and in patients with acute liver failure, 
thrombotic complications are even more common than bleeding in 
patients with acute liver failure in recent series.69
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3.4 | The limited stability of the hemostatic balance 
in liver diseases
Although laboratory and clinical evidence supports the concept of 
rebalanced hemostasis in the “average” patient with liver disease, 
the new hemostatic balance appears much more fragile as com-
pared to the hemostatic balance in patients with intact liver function 
(Figure 1). The limited balance of hemostasis in liver disease is in 
part explained by the low levels of pro- and antihemostatics, but 
may very well also be related to the distinct hypo- and hyperco-
agulable features of the patient with liver disease as discussed in 
the paragraph on “The hemostatic status in patients with cirrhosis.” 
As depicted in Figure 1, the patient with liver disease is constantly 
struggling to remain in hemostatic balance as a result on the low lev-
els of hemostatic factors on each end of the hemostatic scale and by 
dynamic changes in pro- and antihemostatic processes. Therefore, 
it is likely difficult to predict using laboratory tests or clinical scores 
which patient is more likely to tip towards a bleeding diathesis and 
which one is more likely to develop thrombosis. The clinical reality is 
that patients may present with bleeding and thrombosis simultane-
ously, and obviously management of such patients is a particularly 
difficult clinical challenge.
Furthermore, a number of disease- related factors can actively tip 
the balance towards bleeding or thrombosis. Factors that promote 
bleeding include renal failure and infection, both of which are com-
mon in liver disease.73,74 In addition, alterations in flow, endothelial 
activation, disruption of the endothelial glycocalix, and generation of 
procoagulant microparticles all potentially predispose to a thrombotic 
phenotype.
4  | PREVENTION AND MANAGEMENT OF 
BLEEDING IN LIVER DISEASES
4.1 | Bleeding in cirrhosis
We will limit our discussion to the management of “hemostatic” bleed-
ing. Bleeding due to mechanical causes such as ruptured esophageal 
varices and true surgical bleeds are beyond the scope of this review. 
Prevention of bleeding during invasive procedures starts with a very 
restrictive fluid infusion policy the rationale for which is extensively 
outlined by us elsewhere.75,76 As is evident from the liver transplant 
data, routine correction of abnormal routine test of hemostasis (plate-
let count, PT, APTT) by administration of platelet concentrates or 
plasma is not indicated and might even do harm.77 Undesired side- 
effects of blood product administration include fluid overload and ex-
acerbation of portal hypertension (which may paradoxically increase 
bleeding risk) in addition to general transfusion- related side effects. In 
addition, complete correction of prolonged coagulation tests is almost 
never achieved.78 Although some investigators argue that a correc-
tion of the platelet count may be helpful in preventing bleeding in 
high risk procedures,71 clinical data substantiating this are lacking. It 
is even debated whether a low preprocedural platelet count increases 
procedural bleeding risk.47,48 Nevertheless, preprocedural administra-
tion of platelet concentrates are still common, and thrombopoietin 
receptor agonists have been tested in clinical trials and are consid-
ered as potential alternatives for platelet transfusions,79 although they 
may be associated with an risk for thrombotic events.46 Based on our 
experience in liver transplantation, we believe it is best to wait with 
blood product administration until a hemostatic bleed actually occurs. 
F IGURE  1 The hemostatic balance in 
patients with liver disease as compared to 
that of healthy individuals. This cartoon 
depicts the stable hemostatic balance 
in healthy individuals and shows that 
although the hemostatic system in patients 
with liver disease is (re)balanced, the 
balance is fragile and may easily tip to 
either a hypo- or a hypercoagulable status. 
Modified from the European Association 
for the Study of the Liver from Lisman 
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Prophylactic administration of antifibrinolytics have been shown to 
substantially reduce blood product use during liver transplantation, 
and given the relative safety of such agents, they may be helpful in 
a prophylactic setting.80 Prophylactic correction of coagulation by 
low volume products such as prothrombin complex concentrates has 
theoretical advantages over administration of plasma and the effect 
of such agents on blood loss during liver transplantation is currently 
being investigated in a randomized controlled clinical trial.81 Other 
measures that are likely helpful in preventing bleeding is adequate 
control of infections and renal failure. Finally, a structured bleeding 
history should be part of the work- up of patients with liver diseases 
for (elective) invasive procedures, although admittedly the value of 
this screening method for predicting bleeding in this population has 
not been thoroughly investigated.
When bleeding does occur, it is a challenge to decide on the most 
effective pro- hemostatic therapy as bleeding may be caused by failure 
of any of the hemostatic systems (platelets, coagulation, fibrinolysis). 
Thromboelastography may be helpful in deciding which factor(s) re-
quire correction. Although thromboelastography- based transfusion 
algorithms are rapidly gaining popularity,82,83 convincing clinical ev-
idence that such algorithms lead to an optimal restoration of hemo-
static capacity is lacking. Pros and cons of various prohemostatic 
strategies in patients with liver diseases have been discussed by us 
elsewhere.84
4.2 | Bleeding in acute liver failure
Prophylactic administration of blood products in patients with acute 
liver failure is not recommended.10 Not only is the risk of spontane-
ous or procedure- related bleeding low, administration of blood prod-
ucts may cause worsening of intracranial hypertension. Moreover, the 
INR is an important prognostic indicator in acute liver failure, which 
is obscured by administration of plasma. Some authorities have rec-
ommended cautious prophylaxis with recombinant factor VIIa prior 
to high- risk procedures, notably intracranial pressure monitors.85 
However, the uncertain benefit and risk for thrombosis requires fur-
ther evaluation of this strategy before broad use in this setting can be 
recommended.86
5  | PREVENTION AND MANAGEMENT OF 
THROMBOSIS IN LIVER DISEASES
Thrombotic events, including venous thrombosis and portal vein 
thrombosis are frequent in patients with cirrhosis.72,87–90 In addition, 
anticoagulation for arterial events and atrial fibrillation may be required.
There are two major issues with antihemostatic treatment of pa-
tients with liver diseases. First, the liver and kidneys are involved in 
metabolic activation or clearance of a number of the drugs we use 
on a day- to- day basis in general thrombosis management. This results 
in unpredictable pharmacokinetics and for that reason only, some 
of these drugs are contraindicated for patients with liver diseases. 
However, despite these contraindications, the use of contraindicated 
drugs may be desired or deemed essential in selected cases. The un-
predictable pharmacokinetics of anticoagulant drugs necessitates 
careful monitoring, which is a particular challenge in patients with liver 
diseases. Monitoring of vitamin K antagonists is difficult since the INR 
is already prolonged at baseline in patients with advanced disease. In 
such patients, the appropriate target INR has not been established. In 
addition, there is tremendous laboratory- to- laboratory variation in the 
INR in liver disease patients, which complicates studies on optimal tar-
get ranges.6 Recent studies have indicated that monitoring of heparins 
by standard anti- Xa assays give a substantial underestimation of the 
true circulating heparin mass.91,92 In clinical practice the use of anti- Xa 
monitoring of heparins may therefore lead to incorrect and potentially 
dangerous dose escalations. Only anti- Xa assays in which excess exog-
enous antithrombin is present in the reagent give accurate anti- Xa lev-
els in plasma from patients with cirrhosis.91 The second caveat of using 
antihemostatic drugs in patients with liver disease is altered drug po-
tency. The complex hemostatic changes of liver disease were recently 
shown to impact drug potency (at least in vitro).92–94 Using in vitro 
thrombin generation tests it has been demonstrated that the extent by 
which thrombin generation is inhibited by various anticoagulant drugs 
may differ tremendously between patients and controls. The differ-
ential effects were proportional to the severity of disease indicating 
that the extent of alteration in the hemostatic system determines the 
deviation in potency. Confusingly, some drugs appear to have an in-
creased anticoagulant potency, whereas others are less effective in 
plasma from patients with cirrhosis. Although it has not yet been es-
tablished whether these in vitro alterations in potency are relevant in 
vivo, it may be that for optimal management of anticoagulant drugs in 
patients with liver diseases a monitoring test (or combination of tests) 
will be required that assesses both drug levels and drug potency.
As patients with cirrhosis are at risk for venous thrombosis, stan-
dard thromboprophylaxis should be applied upon immobilization, 
hospitalization, and post- surgery, even in patients with a prolonged 
INR. Anticoagulant drugs (LMWH, vitamin K antagonists) have been 
used to treat established portal vein thrombosis, with resolution of the 
thrombus in a proportion of patients.95 Although the safety profile of 
LMWH in this context has been excellent and much better than that of 
vitamin K antagonists, prolonged treatment may be required which is 
a burden for the patient. For this reason, the use of direct oral antico-
agulants is considered by an increasing number of centers,96,97 despite 
the fact that there is virtually no clinical experience with these agents 
in patients with advanced liver disease, which were all excluded from 
the large randomized trials, and the theoretical issues with dosing and 
monitoring. One study has suggested that LMWH is also effective in 
prevention of portal vein thrombosis (PVT),98 but the results of that 
study await confirmation.
6  | INTRAHEPATIC THROMBOSIS AS A 
CONTRIBUTOR TO DISEASE PROGRESSION
The most exciting advance in the field of thrombosis in liver diseases 
is the accumulating evidence of intrahepatic activation of coagulation 
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as a contributor to disease progression. In the 1980s it was first rec-
ognized that microthrombi can be found in rodent models of liver dis-
ease,99,100 and in the 1990s the first reports of microthrombi within 
human livers appeared.101 A functional role of these microthrombi 
has been suggested based on experimental animal models and clinical 
studies. In models of chronic liver disease, anticoagulant or antiplate-
let drugs slow down the progression of disease.101,102 Conversely, 
animals homozygous for factor V Leiden showed accelerated disease 
progression.102 Confusingly, in some models of cholestasis- induced 
fibrosis, complete absence of platelets or fibrinogen paradoxically in-
creases disease progression, suggesting that microthrombi may not 
always be harmful.103,104 Fibrin and platelets have also been impli-
cated in tissue repair mechanisms, which may partly explain the con-
tradictory findings in some models.105,106 Nevertheless, the results of 
human studies outlined in the subsequent paragraphs of this section 
suggest that in humans the harmful actions of intrahepatic coagula-
tion activation are dominant.
In rodent models of acute liver failure, intrahepatic fibrin forma-
tion has also been demonstrated.107 Similar to result in rodent models 
of fibrosis, administration of anticoagulants reduced progression of 
disease in acute liver failure. Activation of coagulation in this model 
was demonstrated to rely on tissue factor expressed on hepato-
cytes.108 Whereas most tissue factor in a healthy liver is in an en-
crypted state, insults such as hepatocyte necrosis induced by acute 
liver failure appear to result in tissue factor decryption, resulting in 
coagulation activation.
Observational studies in humans have suggested a faster disease 
progression of patients with fibrosis who were also carriers of factor V 
Leiden, although not all studies agree.109,110 In addition, patients with 
hemophilia and hepatitis- related fibrosis appeared to have a slower 
disease progression compared to patients with hepatitis without he-
mophilia.111 The combined results of experimental animal studies 
and observational human studies have led to the proposal that an-
ticoagulant drugs may be used as adjunct therapy in patients with 
early cirrhosis to prevent disease progression, decompensation, and 
delay or prevent liver transplantation or death.112 Indeed, a recent 
randomized clinical study showed that prolonged daily administra-
tion of low- molecular- weight heparin substantially delayed decom-
pensation and death, without significant side effects.98 Although 
the results of this study require confirmation, these findings could 
F IGURE  2 Potential mechanisms 
involved in progression of liver disease 
by intrahepatic activation of hemostasis. 
(A) Intrahepatic activation of endothelial 
cells results in the formation of platelet 
microthrombi in the sinusoid. Such 
microthrombi result in disease progression 
via the results of microischemia of the 
downstream tissue. (B) Hepatocellular 
injury results in decryption of hepatocyte 
tissue factor, the generation of thrombin 
(IIa), and eventually fibrin deposition in 
the sinusoid. (C) Concomitant activation 
of hepatocytes and hepatic endothelium 
results in the formation of platelet and 
fibrin- containing microthrombi in the 
sinusoid. (D) Thrombin generated via 
decryption of hepatocyte tissue factor 
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potentially revolutionize the management of cirrhosis, possibly as part 
of a “polypill” program as proposed previously.112 Currently, two ran-
domized controlled trials are assessing efficacy and safety of LMWH 
and rivaroxaban in patients with established cirrhosis with decompen-
sation and survival as primary endpoints (clinicaltrials.gov identifiers 
NCT02643212 and NCT02271295). Whether antihemostatic treat-
ment will also become part of the management of acute liver failure 
is less certain and clinical application may be limited by the perceived 
bleeding risk. Furthermore, a small study conducted in the 1970s 
found no evidence for a beneficial effect of heparin in patients with 
acute liver failure.113
Two hypotheses for the mechanism by which intrahepatic ac-
tivation of coagulation leads to disease progression have been pro-
posed. Initially, the theory of “parenchymal extinction” was proposed, 
in which physical blockade of the microcirculation by platelets, fibrin, 
or a platelet and fibrin- containing thrombus is held responsible for 
the progression of disease.114 In this theory, tissue ischemia caused 
by these microthrombi is held responsible for the effects on disease 
progression. In recent years, a second hypothesis in which cellular ac-
tivation by coagulation proteases is key in driving disease progression 
is gaining popularity. Thrombin (and factor Xa)- mediated activation 
of protease activated receptors on stellate cells results in activation 
of these cells resulting in collagen production by the stellate cells.115 
Alternatively, the mechanism may involve thrombin activation of pro-
tease activated receptors on platelets resulting in the release of profi-
brogenic molecules such as platelet- derived growth factor.3 In models 
of acute liver failure activation of protease- activated receptors also 
contribute to disease progression, although it has not been established 
activation of which cell types are responsible for the effect.107 The 
potential mechanisms explaining the pathogenic role of coagulation 
activation for progression of liver disease are summarized in Figure 2. 
Clearly, the different pathways are not mutually exclusive.
7  | CONCLUSION
The complex hemostatic changes that frequently occur in patients 
with liver diseases results in a “rebalanced” hemostatic system. This 
reset hemostatic balance, however, has a limited stability which ex-
plains the occurrence of both bleeding and thrombotic complica-
tions in these patients. Prediction, prevention management, and 
monitoring of bleeding or thrombosis in patients with liver diseases 
are complicated as a result of the extensive baseline changes in the 
hemostatic system. As such, it is very difficult to provide guidelines 
for management. Some management advice has been published previ-
ously,71,84,116–120 but we would like to stress that most advice is based 
on expert opinion only. Table 2 lists unsolved clinical questions that 
require additional study. Importantly, carefully designed clinical stud-
ies on the efficacy and safety of pro- and antihemostatic strategies 
need to be performed. An exciting area of research regards the use 
of antihemostatic agents to prevent progression of disease. Whether 
such strategies are truly effective and sufficiently safe awaits confir-
mation in larger clinical trials.
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